When Sara Whitlock was diagnosed with stage 4 lung cancer in 2010 at just 47, she feared she wouldn’t live to see her daughters grow up. Her outlook was bleak—only a 3% chance of surviving five years. Yet more than a decade later, Sara is thriving, watching her daughters graduate and enjoying everyday life with her husband. Her journey began with traditional chemotherapy and radiation, but a major turning point came in 2017 when she joined a clinical trial for a gene-targeted therapy called selpercatinib (LOXO-292). The drug is designed for patients with a rare mutation called RET fusion-positive non-small cell lung cancer, found in only about 2% of lung cancer patients.
Sara’s story is a powerful example of how targeted therapies—drugs developed to block specific cancer-driving mutations—are transforming treatment and survival for people with advanced lung cancer. Unlike the harsh side effects of earlier treatments, this pill-based therapy has been easier to tolerate, and Sara currently has no signs of cancer. While she remains aware that her cancer could return, she’s living fully and cherishing every moment. Her story is a reminder that even with a stage 4 diagnosis, new research and personalized treatments are rewriting the possibilities for patients—and their families. (Source: Cleveland Clinic)
